3B Blackbio Dx Limited
3B Blackbio Dx Limited (3BBLACKBIO) financial statements and selected valuation metrics from NSE/BSE exchange filings through 31 December 2025.
Healthcare›Healthcare›Healthcare Services›Healthcare Service Provider
kilpest.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18 Cr | 14 Cr | 19 Cr | 18 Cr | 23 Cr | 19 Cr | 29 Cr | 25 Cr | 22 Cr | 22 Cr | 34 Cr | 50 Cr |
| Operating expenses (approx.) | 11 Cr | 8 Cr | 11 Cr | 9 Cr | 13 Cr | 8 Cr | 13 Cr | 10 Cr | 15 Cr | 10 Cr | 19 Cr | 29 Cr |
| EBITDA | 7 Cr | 6 Cr | 8 Cr | 9 Cr | 10 Cr | 11 Cr | 16 Cr | 15 Cr | 8 Cr | 12 Cr | 15 Cr | 22 Cr |
| OPM % | 41.2% | 45.1% | 40.6% | 50.2% | 43.0% | 56.3% | 55.5% | 59.4% | 35.2% | 53.2% | 43.5% | 43.1% |
| Other income | 1 Cr | 3 Cr | 3 Cr | 3 Cr | 4 Cr | 4 Cr | 3 Cr | 3 Cr | 5 Cr | 4 Cr | 6 Cr | 6 Cr |
| Interest | 0.04 Cr | 0.02 Cr | 0.04 Cr | 0.03 Cr | 0.04 Cr | 0.0062 Cr | 0.03 Cr | 0.02 Cr | 0.04 Cr | 0.01 Cr | 0.04 Cr | 0.09 Cr |
| Depreciation | 0.21 Cr | 0.19 Cr | 0.24 Cr | 0.32 Cr | 0.30 Cr | 0.27 Cr | 0.27 Cr | 0.27 Cr | 0.28 Cr | 0.28 Cr | 0.58 Cr | 0.38 Cr |
| Profit before tax | 8 Cr | 9 Cr | 10 Cr | 11 Cr | 14 Cr | 14 Cr | 19 Cr | 18 Cr | 13 Cr | 16 Cr | 20 Cr | 27 Cr |
| Tax % | 37.9% | 21.6% | 26.0% | 23.6% | 36.0% | 21.3% | 23.0% | 24.2% | 35.9% | 20.3% | 23.4% | 16.4% |
| Net profit | 5 Cr | 7 Cr | 8 Cr | 9 Cr | 9 Cr | 11 Cr | 15 Cr | 13 Cr | 8 Cr | 13 Cr | 15 Cr | 22 Cr |
| EPS (₹) | ₹6.92 | ₹9.60 | ₹8.86 | ₹9.94 | ₹10.26 | ₹13.19 | ₹17.35 | ₹15.75 | ₹9.38 | ₹14.76 | ₹17.55 | ₹26.19 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 23 Cr | 29 Cr | 227 Cr | 81 Cr | 62 Cr | 74 Cr | 96 Cr | Sign in for TTM |
| Operating expenses (approx.) | 16 Cr | 20 Cr | 77 Cr | 44 Cr | 33 Cr | 41 Cr | 46 Cr | Sign in for TTM |
| EBITDA | 7 Cr | 9 Cr | 150 Cr | 37 Cr | 29 Cr | 33 Cr | 50 Cr | Sign in for TTM |
| OPM % | 31.0% | 32.3% | 66.1% | 46.0% | 47.1% | 44.5% | 51.9% | Sign in for TTM |
| Other income | 0.74 Cr | 2 Cr | 3 Cr | 7 Cr | 7 Cr | 13 Cr | 15 Cr | Sign in for TTM |
| Interest | 0.46 Cr | 0.33 Cr | 0.23 Cr | 0.11 Cr | 0.20 Cr | 0.12 Cr | 0.11 Cr | Sign in for TTM |
| Depreciation | 0.55 Cr | 0.54 Cr | 0.62 Cr | 0.67 Cr | 0.86 Cr | 1 Cr | 1 Cr | Sign in for TTM |
| Profit before tax | 7 Cr | 10 Cr | 152 Cr | 43 Cr | 35 Cr | 44 Cr | 64 Cr | Sign in for TTM |
| Tax % | 24.6% | 23.5% | 25.1% | 25.5% | 26.5% | 27.6% | 25.5% | Sign in for TTM |
| Net profit | 5 Cr | 8 Cr | 114 Cr | 32 Cr | 26 Cr | 32 Cr | 48 Cr | Sign in for TTM |
| EPS (₹) | ₹8.18 | ₹10.22 | ₹151.68 | ₹42.89 | ₹34.55 | ₹37.46 | ₹55.66 | Sign in for TTM |
| Dividend payout % | — | — | — | 48.0% | 17.1% | 6.8% | 5.4% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 6 Cr | 7 Cr | 7 Cr | 7 Cr | 7 Cr | 9 Cr | 9 Cr |
| Reserves | 16 Cr | 25 Cr | 125 Cr | 146 Cr | 164 Cr | 214 Cr | 260 Cr |
| Borrowings | 6 Cr | 4 Cr | 2 Cr | 3 Cr | 2 Cr | 0.85 Cr | 0.31 Cr |
| Other liabilities | 7 Cr | 7 Cr | 43 Cr | 17 Cr | 16 Cr | 22 Cr | 24 Cr |
| Total liabilities | 36 Cr | 45 Cr | 194 Cr | 192 Cr | 214 Cr | 248 Cr | 296 Cr |
| Fixed assets (net) | 4 Cr | 4 Cr | 5 Cr | 7 Cr | 8 Cr | 7 Cr | 7 Cr |
| CWIP | 0.10 Cr | 0.20 Cr | 0.13 Cr | 0.11 Cr | 0.09 Cr | — | — |
| Investments | 1 Cr | 1 Cr | 70 Cr | 104 Cr | 92 Cr | 117 Cr | 156 Cr |
| Loans & advances | 0.05 Cr | 0.06 Cr | 0.10 Cr | 0.08 Cr | 0.09 Cr | 0 Cr | 0 Cr |
| Inventories | 5 Cr | 4 Cr | 5 Cr | 7 Cr | 8 Cr | 8 Cr | 9 Cr |
| Trade receivables | 18 Cr | 20 Cr | 35 Cr | 30 Cr | 34 Cr | 36 Cr | 37 Cr |
| Cash & bank | 2 Cr | 9 Cr | 2 Cr | 3 Cr | 6 Cr | 14 Cr | 12 Cr |
| Other assets | 6 Cr | 7 Cr | 77 Cr | 41 Cr | 66 Cr | 65 Cr | 74 Cr |
| Total assets | 36 Cr | 45 Cr | 194 Cr | 192 Cr | 214 Cr | 248 Cr | 296 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 37 Cr | 23 Cr | 27 Cr | 43 Cr |
| Cash from investing | — | — | — | -28 Cr | 12 Cr | -20 Cr | -34 Cr |
| Cash from financing | — | — | — | -15 Cr | -5 Cr | -4 Cr | -3 Cr |
| Net cash flow | — | — | — | -6 Cr | 30 Cr | 3 Cr | 7 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 35 Cr | 23 Cr | 27 Cr | 42 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| ROCE % | 25.6% | 27.5% | 101.3% | 24.8% | 17.9% | 19.6% | 23.6% |
| ROE % | 22.1% | 19.9% | 67.3% | 16.4% | 11.6% | 14.5% | 17.6% |
| Debtor days | 289 | 252 | 56 | 135 | 200 | 178 | 138 |
| Inventory days | 162 | 112 | 35 | 88 | 163 | 155 | 122 |
| Days payable | 127 | 93 | 21 | 42 | 68 | 73 | 28 |
| Cash conversion cycle | 324 | 271 | 70 | 181 | 294 | 261 | 233 |
| Debt / equity | 0.28 | 0.11 | 0.02 | 0.02 | 0.01 | 0.0038 | 0.0011 |
| Current ratio | 3.08 | 4.82 | 2.76 | 4.82 | 8.05 | 7.04 | 7.11 |
| Net debt / EBITDA | 0.59 | -0.60 | 0.0001 | -0.02 | -0.14 | -0.39 | -0.24 |
Compare with peers
Loading peers…